First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
1. Pumitamig shows 76.3% confirmed objective response in ES-SCLC treatment. 2. 100% disease control rate observed alongside mPFS of 6.8 months. 3. Ongoing Phase 3 trial will validate pumitamig's potential. 4. Pumitamig received FDA Orphan Drug designation for small cell lung cancer. 5. Positive interim results suggest a potential new standard of care.